江苏吴中为进口童颜针代理权索赔16亿，爱美客称新品牌已开售

Core Viewpoint - The dispute over the exclusive agency rights for AestheFill between Jiangsu Wuzhong and Aimeike has escalated, with Jiangsu Wuzhong initiating arbitration against REGEN for breach of contract after REGEN terminated their exclusive distribution agreement [1][2]. Group 1: Arbitration and Legal Actions - Jiangsu Wuzhong announced on August 11 that it has filed for arbitration with the Shenzhen International Arbitration Court regarding REGEN's breach of contract, seeking to confirm the validity of the exclusive agency agreement for AestheFill until August 28, 2032 [1][2]. - The arbitration request includes demands for REGEN to supply AestheFill products as per the agreement, and if not supported, for REGEN to compensate Jiangsu Wuzhong for losses estimated at RMB 1.6 billion [1][2]. Group 2: Financial Impact and Market Position - As of August 12, Jiangsu Wuzhong's stock price was reported at RMB 1.08 per share, with a market capitalization of RMB 768 million, while Aimeike's stock was at RMB 188.45 per share, with a market capitalization of RMB 57.02 billion [1]. - AestheFill, which was launched in April 2024, contributed over RMB 300 million in revenue to Jiangsu Wuzhong within eight months, highlighting its significance to the company's financial recovery [4][9]. Group 3: Company Strategies and Responses - Following the termination of the agreement, Jiangsu Wuzhong initiated the "W Sunshine Guardian Plan," providing free repair treatments to clients who previously received AestheFill treatments, while also offering training support to partner institutions [11]. - Aimeike has begun selling AestheFill under a new brand name "Zhen Ai Su Fei" in the domestic market, indicating a shift in branding strategy post-dispute [11]. Group 4: Background and Context - The agency rights dispute has roots in Aimeike's acquisition of REGEN in March 2025, which raised concerns about the future of AestheFill's distribution rights [8]. - The legal conflict is compounded by both companies facing performance pressures, with Aimeike's revenue growth slowing significantly and Jiangsu Wuzhong previously reporting six consecutive years of net losses [9].